Xeris Pharmaceuticals, Inc.

Terapio Corporation

Disruption Labs Inc.

Brian R Sloat

Michael A Sandoval

Steven J Prestrelski

Casey C Cunningham

Tyler B West

Sonika Saddar

Embodiments of the invention are directed to formulations that provide a solution to the problem of small molecule (e.g., diazepam) precipitation at the injection site when administered as a highly-concentrated formulation. In certain aspects the formulations include at least one surfactant in a non-aqueous formulation, which prevents small molecule precipitation and improves the bioavailability of the drug by enhancing absorption into the systemic circulation.

Precipitation resistant small molecule drug formulations

Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of CBD to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.

Compositions for the delivery of therapeutic agents and methods of use and making thereof

Provided herein are methods of preventing or reducing the effects of exposure to a mustard compound. The methods include the steps of contacting cells exposed to a mustard compound or at risk of exposure to a mustard compound with a composition comprising a polypeptide comprising RLIP76 or an active fragment or variant thereof. Optionally, the methods include the steps of administering to a subject exposed to a mustard compound or at risk of exposure to a mustard compound a composition comprising a polypeptide comprising RLIP76 or an active fragment or variant thereof.

Methods of reducing the effects of exposure to a mustard compound by administering RLIP76

Growing community of inventors

Austin, TX, United States of America

Brian R Sloat